INS and type 2 diabetes mellitus: Another real-world study, ATOS (NCT03703869), was conducted prospectively across multiple countries (n = 388) for a period of one-year (n = 4589 participants) to assess the clinical effectiveness, safety and health-economic benefits of Gla-300 initiation in insulin-naïve people with T2DM who failed to achieve glycemic control with OADs [24].